Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC QL47B TFA | 96.0% | 992.07 | 5 MG
QL47B TFA is a biotinylated analogue of QL47 (HY-80003), functioning as a potent inhibitor of BTK with an IC50 value of 1.3 μM. It also exhibits anti-tumor activity.
- Potent inhibitor of BTK (IC50 value of 1.3 μM).
- Exhibits anti-tumor activity.
Medchemexpress LLC Clovibactin TFA | 97.1% | 903.08 | 1 MG
Clovibactin TFA is the TFA salt form of Clovibactin (HY-P10027), serving as an antibiotic for drug-resistant bacterial pathogens without detectable resistance. It functions by inhibiting cell wall synthesis, specifically targeting pyrophosphate of peptidoglycan precursors.
- Effective against drug-resistant bacterial pathogens.
- No detectable resistance observed.
- Inhibits cell wall synthesis through a specific mechanism targeting peptidoglycan precursors.
- Demonstrates inhibition of Staphylococcus strains with MICs ranging from 0.125-2 μg/mL in vitro.
- Exhibits a characterized pharmacokinetic profile in mice, including a Cmax of 219.3 μg/mL and a t1/2 of 2 hours following a 20 mg/kg intravenous single dose.
Medchemexpress LLC Alpha-Melanocyte-Stimulating Hormone TFA | 171869-93-5 | 98.5% | 1 MG
α-MSH TFA (α-Melanocyte-Stimulating Hormone TFA) is an endogenous neuropeptide and a melanocortin receptor 4 (MC4R) agonist. It exhibits anti-inflammatory and antipyretic activities and is a post-translational derivative of pro-opiomelanocortin (POMC).
- Endogenous neuropeptide
- MC4R agonist with anti-inflammatory and antipyretic activities
- Post-translational derivative of pro-opiomelanocortin (POMC)
- Modulates CNS inflammation by acting directly on melanocortin receptors in glial cells
- Modulates NFκB activation
- Inhibits translocation of transcription factor κB to the nucleus
Medchemexpress LLC GpTx-1 TFA | 99.6% | 4073.82 (free base) | 1 MG
GpTx-1 TFA is a peptide-based NaV1.7 sodium channel antagonist isolated from the venom of the Chilean spider Grammostola porter. It demonstrates potent inhibitory activity against the NaV1.7 channel with an IC50 value of 10 nM. It also exhibits excellent selectivity for NaV1.4 (IC50 = 0.301 μM) and NaV1.5 (IC50 = 4.20 μM), demonstrating >20-fold and >950-fold selectivity, respectively. This product is for research use only.
- Potent inhibitory activity against NaV1.7 channel with an IC50 value of 10 nM.
- Exhibits >20-fold selectivity for NaV1.4 (IC50 = 0.301 μM).
- Exhibits >950-fold selectivity for NaV1.5 (IC50 = 4.20 μM).
- Isolated from the venom of the Chilean spider Grammostola porter.
Medchemexpress LLC WP9QY (TFA) | 199999-60-5 | 98.7% | 1340.40 | 25 MG
WP9QY TFA is a biologically active cyclic peptide, serving as a TNF-α Antagonist. It is designed to mimic the critical tumor necrosis factor (TNF) recognition loop on TNF receptor I, preventing interactions of TNF with its receptor. This peptide is a useful template for developing small molecular inhibitors to prevent inflammatory bone destruction and systemic bone loss in rheumatoid arthritis. It is for research use only.
- Biologically active peptide
- TNF-α antagonist
- Mimics critical tumor necrosis factor recognition loop on TNF receptor I
- Prevents TNF interactions with its receptor
- Useful template for small molecular inhibitor development
- Prevents inflammatory bone destruction
- Prevents systemic bone loss in rheumatoid arthritis
- For research use only
Medchemexpress LLC LARLLT (TFA) | 99.9% | 799.88 | 5 MG
LARLLT (TFA) is an EGFR-binding peptide with potential for research into EGFR overexpressing cancers, including lung, ovarian, and colorectal cancer.
- EGFR-binding peptide
- Potential for research of EGFR overexpressing cancers
- Targets EGFR
- Involves JAK/STAT signaling and protein tyrosine kinase/RTK pathways
- Sequence: Leu-Ala-Arg-Leu-Leu-Thr
- Molecular weight of 799.88
- Purity of 99.9% (HPLC)
- Soluble in DMSO: 50 mg/mL
- Appears as a white to off-white solid
- Powder storage: -80°C for 2 years, -20°C for 1 year
- In solvent storage: -80°C for 6 months, -20°C for 1 month (sealed storage, away from moisture)
Medchemexpress LLC TAT peptide TFA | 99.8% | 1735.93 | 25 MG
TAT peptide (TFA) is a cell penetrating peptide (GRKKRRQRRRPQ) derived from the trans-activating transcriptional activator (Tat) from HIV-1. It has been studied in functionalized hybrid nanoparticles for magnetic enrichment and optical detection in cell separation and rapid cell labelling, demonstrating good biocompatibility.
- Derived from trans-activating transcriptional activator (Tat) from HIV-1
- Cell penetrating peptide (GRKKRRQRRRPQ)
- Used in functionalized hybrid nanoparticles for cell separation
- Used in rapid cell labelling
- Shows good biocompatibility
- For research use only
Medchemexpress LLC Psalmotoxin 1 TFA | 880107-52-8 | 99.37% | 4689.39 | 500 UG
Psalmotoxin 1 is a protein toxin that binds at subunit-subunit interfaces of acid-sensing ion channel 1a (ASIC1a). It acts as a potent and selective ASIC1a inhibitor by increasing the apparent affinity for H+ of ASIC1a. Psalmotoxin 1 can induce cell apoptosis and inhibit cell migration, proliferation, and invasion of cancer cells. It is utilized in research concerning cancers and neurological diseases.
- Potent and selective ASIC1a inhibitor with an IC50 of 0.9 nM
- Induces cell apoptosis
- Inhibits cell migration, proliferation, and invasion of cancer cells
- Used in research concerning cancers and neurological diseases
- Neuroprotective in a conscious model of stroke
- Inhibits tumor growth in breast cancer models
Medchemexpress LLC AT-1002 TFA | 835872-35-0 | 99.5% | 821.91 | 1 ML
AT-1002 TFA, a 6-mer synthetic peptide, is a tight junction regulator and absorption enhancer. It belongs to an emerging novel class of compounds that reversibly increase paracellular transport of molecules across the epithelial barrier.
- Can undergo Cys-Cys dimerization.
- Treatment for up to 3 hours did not affect Caco-2 cell viability at any concentration.
- Reduced cell viability after 24 hours at concentrations of 2.5 mg/mL and higher.
- Cells remained viable after 24 hours if washed after 3 hours exposure, indicating it does not irreversibly damage cells.
Medchemexpress LLC KLD-12 TFA | 95.22% | 1467.79 | 5 MG
KLD-12 TFA is the TFA salt form of KLD-12, a 12-residue self-assembling peptide. It is used in tissue engineering and, when combined with SDF-1 self-assembled polypeptide, enhances chondrogenic differentiation of bone marrow stromal cells (BMSCs). The hydrogel form can fill full-thickness osteochondral defects in situ and improve cartilage repair. In vivo, it promotes bone regeneration at the fracture site in a dose-dependent manner.
- Enhances chondrogenic differentiation of bone marrow stromal cells
- Forms self-assembled polypeptide with SDF-1
- Improves survival of bone marrow stromal cells
- Promotes osteogenic differentiation of bone marrow stromal cells and cell migration via Wnt/β-catenin pathway
- Promotes bone regeneration at the fracture site
Medchemexpress LLC Fn-439 TFA | 124168-73-6 | MFCD00237459 | 99.8% | 604.58 g·mol⁻¹ | C25H35F3N6O8 | 5 MG
FN-439 TFA is the trifluoroacetic acid salt of FN-439, a selective small-molecule inhibitor of collagenase-1 (matrix metalloproteinase). It inhibits collagenase-1 with an IC50 of 1 μM and is supplied as a research reagent for in vitro studies of cancer and inflammatory processes.
- Selective collagenase-1 inhibitor with reported IC50 of 1 μM.
- High purity (99.81%) suitable for biochemical assays.
- Trifluoroacetic acid salt form to aid solubility in aqueous systems.
- Supplied in research-scale quantities (e.g., five mg) for assay development.
- Intended for in vitro research applications; not for human use.
Medchemexpress LLC FTI-2153 (TFA) | 2820151-01-5 | 99.1% | 580.62 g/mol | C27H31F3N4O5S | 10MM 1ML
FTI-2153 TFA is the trifluoroacetic acid salt of a potent farnesyltransferase inhibitor supplied for research use. It is provided as a ready-to-use 10 mM solution in DMSO (1 mL) and in solid amounts, with supporting datasheet, SDS, and COA for characterization and safe handling.
Medchemexpress LLC AS-99 TFA | 99.1% | C29H31F6N5O5S2 | 1 MG
AS-99 TFA is a first-in-class, potent, and selective ASH1L histone methyltransferase inhibitor (IC50 of 0.79 μM, Kd of 0.89 μM) with anti-leukemic activity. It functions by blocking cell proliferation, inducing apoptosis and differentiation, downregulating MLL fusion target genes, and reducing the leukemia burden in vivo.
- Potent and selective ASH1L histone methyltransferase inhibitor
- Demonstrates anti-leukemic activity
- Blocks cell proliferation
- Induces apoptosis and differentiation
- Downregulates MLL fusion target genes
- Reduces leukemia burden in vivo
- Exhibits over 100-fold selectivity towards ASH1L over 20 other histone methyltransferases
- Suppresses MLL fusion driven transcriptional programs
- Leads to dose-dependent downregulation of canonical MLL fusion target genes
Medchemexpress LLC Ac-Cys-Pro-Pro-Tyr-Leu-Pro-cyclo(Lys-Tyr-Leu-Cys-Asp)-Leu-Ile-NH2 (disulfide bridge :Cys1-Cys10) | 99.0% | 1672.93 | 10 MG
KS-133 TFA is a highly selective and potent antagonist of the vascular active enteropeptide receptor 2 (VIPR2), primarily used in research for schizophrenia and cancer immune regulation.
- Highly selective and potent VIPR2 antagonist.
- Reverses tumor-promoting M2 macrophage phenotype to anti-tumor M1, altering tumor immune microenvironment.
- Inhibits tumor growth.
- Can be formulated as nanoparticles to cross the blood-brain barrier.
- Enhances anti-tumor and neuroprotective activities.
- Prevents VIPR2 over-activation, safeguarding against cognitive impairments and neuronal structural damage in mice.
- Demonstrates anti-tumor activity in murine models, synergistic with anti-PD-1 antibodies.
Apexbio Technology LLC BIBP 3226 trifluoroacetate(Synonyms: BIBP3226 TFA, BIBP3226 trifluoroacetate salt, NPY Y1 receptor antagonist BIBP3226), 2mg, CAS: 1068148-47-9.
BIBP 3226 trifluoroacetate (CAS 1068148-47-9) is a non-peptide antagonist targeting neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptors showing binding affinity with Ki values of 1 1 nM (rNPY Y1) 79 nM (hNPFF2) and 108 nM (rNPFF) BIBP 3226 competes with NPFF prevents NPFF-induced inhibition of forskolin-stimulated cAMP production and blocks NPFF-dependent hypothermic and anti-opioid effects in rodent models This compound is employed experimentally to investigate NPY/NPFF system roles in anxiety analgesia and cardiovascular regulation